Improving uptake of the drug, a component of Paxlovid, could help reduce longer term outcomes, as well as severe disease, the authors said.
Nirmatrelvir tied to 26% lower risk of long COVID, 47% lower risk of death
Published in COVID-19
More from COVID-19More posts in COVID-19 »
- Global, US data show high antibiotic use, rise in resistant infections during COVID
- US respiratory virus levels continue to decline as officials track shift in SARS-CoV-2 proportions
- Study reveals promising results for abatacept for severe COVID
- Long-COVID patients more likely to report psychiatric symptoms, cost barriers to therapy